Indeed, CCL2 was required for these anti-tumor immune effects, as CCL2 blockade reduced NK cell accumulation, abolished tumor regressions, and significantly mitigated the survival benefit and number of complete responders to combined EZH2 knockdown and T/P treatment (Fig. 6g–i). The gene discussed is CCL2; the disease is neoplasm.